KUZIK SI DIMOSTRA EFFICACE NELLA PREVENZIONE DELL’ EMICRANIA SENZA AURA
Our study has demonstrated the efficacy of Kuzik® in the improvement of episodic MO with a reduction at least of 50% in the frequency of attacks per month (51%) and in MIDAS disability score (84%). Kuzik® was well tolerated and allowed a reduction of 50% of symptomatic drug assumptions in 43% of patients treated. On the basis of these data, we suggest that the use of Kuzik® may have a role in the prophylactic treatment of MO.
Questo sito utilizza i cookie per offrirvi una migliore esperienza di navigazione. I cookie sono file memorizzati nel browser e sono utilizzati dalla maggior parte dei siti per personalizzare l'esperienza web.
Continuando la navigazione accetterai l'utilizzo dei cookies. Privacy e Cookie PolicyAccetta Cookie
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.